Literature DB >> 25916510

Nonparametric discrete survival function estimation with uncertain endpoints using an internal validation subsample.

Jarcy Zee1, Sharon X Xie1.   

Abstract

When a true survival endpoint cannot be assessed for some subjects, an alternative endpoint that measures the true endpoint with error may be collected, which often occurs when obtaining the true endpoint is too invasive or costly. We develop an estimated likelihood function for the situation where we have both uncertain endpoints for all participants and true endpoints for only a subset of participants. We propose a nonparametric maximum estimated likelihood estimator of the discrete survival function of time to the true endpoint. We show that the proposed estimator is consistent and asymptotically normal. We demonstrate through extensive simulations that the proposed estimator has little bias compared to the naïve Kaplan-Meier survival function estimator, which uses only uncertain endpoints, and more efficient with moderate missingness compared to the complete-case Kaplan-Meier survival function estimator, which uses only available true endpoints. Finally, we apply the proposed method to a data set for estimating the risk of detecting Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative.
© 2015, The International Biometric Society.

Entities:  

Keywords:  Measurement error; Missing data; Nonparametric survival analysis; Uncertain endpoints; Validation sample

Mesh:

Year:  2015        PMID: 25916510      PMCID: PMC4575242          DOI: 10.1111/biom.12316

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Estimation of the timing of perinatal transmission of HIV.

Authors:  R Balasubramanian; S W Lagakos
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Product limit estimation for infectious disease data when the diagnostic test for the outcome is measured with uncertainty.

Authors:  B A Richardson; J P Hughes
Journal:  Biostatistics       Date:  2000-09       Impact factor: 5.899

3.  Discrete proportional hazards models for mismeasured outcomes.

Authors:  Amalia S Meier; Barbra A Richardson; James P Hughes
Journal:  Biometrics       Date:  2003-12       Impact factor: 2.571

Review 4.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

5.  Survival analysis with uncertain endpoints.

Authors:  S M Snapinn
Journal:  Biometrics       Date:  1998-03       Impact factor: 2.571

6.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.

Authors:  T R Fleming; R L Prentice; M S Pepe; D Glidden
Journal:  Stat Med       Date:  1994-05-15       Impact factor: 2.373

Review 7.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

8.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

9.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

10.  Incorporating validation subsets into discrete proportional hazards models for mismeasured outcomes.

Authors:  Amalia S Magaret
Journal:  Stat Med       Date:  2008-11-20       Impact factor: 2.373

  10 in total
  2 in total

1.  Assessing treatment effects with surrogate survival outcomes using an internal validation subsample.

Authors:  Jarcy Zee; Sharon X Xie
Journal:  Clin Trials       Date:  2015-05-14       Impact factor: 2.486

2.  Interval-censored data with misclassification: a Bayesian approach.

Authors:  Magda Carvalho Pires; Enrico Antônio Colosimo; Guilherme Augusto Veloso; Raquel de Souza Borges Ferreira
Journal:  J Appl Stat       Date:  2020-04-16       Impact factor: 1.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.